Predisposing factors for Hoffa's fat pad syndrome: a systematic review.
Diego Agustín Abelleyra Lastoria, Clerin Kulangara Benny, Caroline Blanca Hing
https://pubmed.ncbi.nlm.nih.gov/37296488/Actively Recruiting
Led by Boston Children's Hospital · Updated on 2026-03-23
62
Participants Needed
1
Research Sites
8 weeks
Total Duration
This research aims to evaluate treatment outcomes for refractory anterior knee pain caused by Hoffas Fat Pad Impingement HFPI in young female athletes aged 12 to 18 years. The study focuses on pediatric female athletes with HFPI and compares outcomes of ultrasound-guided corticosteroid injections into the Hoffas fat pad against standard care, which includes physical therapy with either saline injections or no injection. The research does not assess the safety or effectiveness of the lidocaine-methylprednisolone mixture used in the corticosteroid injection. Participants will be randomly assigned to one of two groups the intervention group receiving an ultrasound-guided corticosteroid injection plus physical therapy, or the control group receiving a saline injection with physical therapy. Both treatments are administered at the study visit. The corticosteroid injections are a common procedure at Boston Childrens Hospitals sports medicine clinic, while saline injections serve as a placebo. Patient-reported outcomes such as quality of life, pain interference, symptoms, function, and activity level will be collected at 4 and 8 weeks post-injection. Throughout the study, participants will report on their knee function and pain using tools like the International Knee Documentation Committee IKDC score, Peds Quality of Life Score, and PROMIS Pain Interference Short Form from enrollment through 8 weeks after. Researchers will also track activity levels weekly and any pain flare-ups at 4 weeks post-injection. The total participation duration covers up to 8 weeks following enrollment, with regular assessments to monitor treatment impact and patient well-being.
CONDITIONS
Hoffa's Fat Pad Impingement (HFPI)
O
Olivia Elie, B.S.
D
Dai Sugimoto, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Boston Children's Hospital
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ultrasound-Guided Corticosteroid Injection | Ultrasound-Guided Saline Injection (Placebo) |
|---|---|---|
| What it is | An ultrasound-guided injection of methylprednisolone acetate (a corticosteroid) and lidocaine directly into the infrapatellar (Hoffa's) fat pad to reduce pain and inflammation. | An ultrasound-guided saline injection into the Hoffa's fat pad, serving as a placebo for comparison with the active drug injection. |
| Role in trial | Investigational treatment arm tested for effectiveness in improving pain and function in adolescents with HFPI. | Comparison placebo arm to allow controlled assessment of the corticosteroid injection's effect. |
| Primary use | Designed to reduce inflammation and improve pain, symptoms, and knee function in adolescent females with Hoffa's Fat Pad Impingement. | Serves as an inactive control to evaluate treatment outcomes against active intervention. |
| How it is given/performed | Administered as a single ultrasound-guided injection into the infrapatellar (Hoffa’s) fat pad during a study visit. | Given as a single ultrasound-guided saline injection into the Hoffa’s fat pad during a study visit. |
| Evidence status | Clinical studies and reviews support corticosteroid injection as a commonly used intervention for Hoffa's Fat Pad pain, though high-quality pediatric data remain limited and trial results are still awaited for this adolescent population. | Saline injection serves as a control and does not have expected therapeutic benefit for HFPI; outcomes provide a baseline for study comparison. |
| Important limitations | May provide only temporary relief; effectiveness and longer-term safety for adolescents with HFPI are still under study. Published evidence in this specific population and age group is limited. | No expected pain or functional improvement; included for comparison but is not considered therapeutic. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single visit
Participants receive either an ultrasound-guided corticosteroid injection or a saline injection to the Hoffa's fat pad at a single visit.
1 injection visit (in-person)
Duration - 8 weeks
Participants complete patient-reported outcome assessments including quality of life, pain interference, symptoms and function, and level of activity at 4 weeks and 8 weeks after the injection.
2 remote assessments at 4 weeks and 8 weeks post-injection
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Diego Agustín Abelleyra Lastoria, Clerin Kulangara Benny, Caroline Blanca Hing
https://pubmed.ncbi.nlm.nih.gov/37296488/Megan K Mills, Hailey Allen
https://pubmed.ncbi.nlm.nih.gov/35512891/Ty K Subhawong, John Eng, John A Carrino...
https://pubmed.ncbi.nlm.nih.gov/21098197/Florent Eymard, Xavier Chevalier
https://pubmed.ncbi.nlm.nih.gov/27068617/Georg C Feuerriegel, Adrian A Marth, Stefan Fröhlich...
https://pubmed.ncbi.nlm.nih.gov/38365902/Jason L Dragoo, Christina Johnson, Jenny McConnell
https://pubmed.ncbi.nlm.nih.gov/22149697/Matthew Bessette, Paul Saluan
https://pubmed.ncbi.nlm.nih.gov/27811513/Nicole B Katz, Nicholas Tsitsilianos, Andrew S Nowak...
https://pubmed.ncbi.nlm.nih.gov/39527393/C B Chung, A Skaf, B Roger...
https://pubmed.ncbi.nlm.nih.gov/11810167/C V House, D A Connell
https://pubmed.ncbi.nlm.nih.gov/17981168/Boston Children's Hospital
Lead Sponsor